15.4.2021 19:29:28 CEST | Aqua Bio Technology ASA | Mandatory notification of trade primary insiders
Aqua Bio Technology ASA: Notifiable transaction in connection with Private Placement
Reference is made to the stock exchange notice from Aqua Bio Technology ASA (the “Company”) on 15 April 2021 regarding completion of a private placement raising gross proceeds of approximately NOK 15 million through issuance 1,303,707 new shares (the “Private Placement”).
In order to arrange settlement for certain of the new shares to be delivered in the Private Placement, a share lending arrangement has been agreed with Kjeveortoped Espen Dahl AS, a close associate of Board member Kristin Aase. Pursuant to this arrangement, Kjeveortoped Espen Dahl AS has agreed to lend out 605,017 shares in the Company. Please see the attached form for further information.
* * *
For further information, please contact Edvard Cock, Chairman, telephone +47 415 05 004.
Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT’s cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. ABT’s focus on commercialization and development of natural ingredients and natural skin care products has been, and will continue to be, an important part of the Company’s strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.
This information is such that Aqua Bio Technology ASA is required to disclose in accordance with the EU Market Abuse Regulation, and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. The stock exchange announcement was published by Håvard Lindstrøm, Head of Business Development, on 15 April 2021, at 19:30 CEST.
Disclaimer
This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.
Contacts
Espen Kvale, CEO, +47 916 28 092, espen.kvale@aquabiotech.no
About Aqua Bio Technology ASA
Aqua Bio Technology (ABT) is developing and commercializing sustainablebiotechnology for use in skin care products. ABT’s cosmetics ingredients arehighly effective and they provide the cosmetics industry with naturalalternatives to traditional ingredients. ABT is also marketing and distributingnatural skin care products developed by partners towards consumers andprofessional users. Aqua Bio Technology is listed on Euronext Expand.
Attachments
Download announcement as PDF.pdf
Notification and public disclosure of transactions by Primary Insiders and their Close Associates 15 april 2021.pdf
